Vyjuvek Coupons & Prices

Looking for help paying for Vyjuvek? Vyjuvek (beremagene geperpavec-svdt, often shortened to B-VEC) is a brand-only topical gene therapy for wounds in adults and children with dystrophic epidermolysis bullosa (DEB) caused by mutations in the COL7A1 gene. There is no generic version. Vyjuvek is not a medicine you pick up off the shelf at a retail pharmacy counter: it is a specialty biologic that is prepared for each patient at a designated pharmacy and shipped through a limited distribution network, so a standard discount-card cash price is generally not how this one gets paid for. What you actually pay is driven by your insurance benefit and by the manufacturer's patient support program. Read on for how coverage, the manufacturer's program, and the specialty pharmacy path work for Vyjuvek.

What is Vyjuvek and how does it work?

Vyjuvek is the first FDA-approved redosable topical gene therapy (first approved in May 2023). It is approved to treat wounds in adult and pediatric patients with dystrophic epidermolysis bullosa who have one or more mutations in the collagen type VII alpha 1 chain (COL7A1) gene. It is used for both recessive and dominant forms of DEB, and DEB wounds are its only indication.

People with DEB cannot make enough working type VII collagen, the protein that anchors the top layer of skin to the layer beneath it, so the skin blisters and tears easily. Vyjuvek uses a modified herpes simplex virus type 1 (HSV-1) vector that cannot replicate and does not integrate into your DNA. The vector carries two copies of the full-length human COL7A1 gene into skin cells at the wound, so those cells can make functional type VII collagen. A pharmacy prepares the biological suspension into the supplied excipient gel, and the gel is applied to the wound once a week. The dose depends on the patient's age: the current label sets a lower maximum weekly dose and volume for children under 3 years than for patients 3 years and older. As of the September 2025 label revision, there is no minimum age for treatment, and the prepared gel may be applied by a healthcare professional, the patient, or a caregiver, either in a clinic or at home.

Vyjuvek cost: insurance, the manufacturer program, and specialty pharmacy

Vyjuvek is a brand-only biologic with no generic, and it is dispensed through a limited distribution network rather than stocked at neighborhood pharmacies. Because of that, there is usually no meaningful "cash price at the counter" to shop for, and a discount card is not a realistic way to pay for this therapy. Coverage is the lever that matters.

Krystal Biotech runs an official patient support program for Vyjuvek (Krystal Connect), which you can find through the manufacturer's official Vyjuvek website. Programs like this generally include a benefits investigation, help with prior authorization, a commercial copay savings offer, and information about patient assistance for people who qualify. Manufacturer copay cards are usually limited to people with commercial (non-government) insurance and are typically not available if you have Medicare, Medicaid, TRICARE, or other federal coverage. Terms, eligibility, and any limits vary and can change, so confirm the current details directly with the manufacturer's program.

If you have Medicare, Medicaid, or another government plan, or if you are uninsured, ask the manufacturer's program about patient assistance and ask your DEB care team and the specialty pharmacy what coverage pathways and appeals are available to you. For a therapy like Vyjuvek, the manufacturer's program, your plan's coverage determination, and the appeals process are what move the number you pay, not a coupon.

Is there a generic or an alternative to Vyjuvek?

There is no generic version of Vyjuvek. It is a biologic gene therapy, not a small-molecule pill, so there is no substitutable generic at the pharmacy and no lower-cost interchangeable product to ask for. That means the savings levers are your insurance benefit and the manufacturer's support and assistance program.

Vyjuvek is not the only prescription option for epidermolysis bullosa wounds, and the available products work in very different ways. Filsuvez (birch triterpenes) is a topical gel used for wound care in epidermolysis bullosa; it is applied to the wound and covered with a dressing, and it does not deliver a gene. Zevaskyn (prademagene zamikeracel), approved by the FDA in April 2025, is a cell-based gene therapy for wounds in patients with recessive DEB: a patient's own skin cells are gene-modified to carry a working COL7A1 gene, grown into sheets, and surgically applied to wounds in a one-time procedure. Vyjuvek is the only topical, redosable gene therapy that is applied directly to wounds and reapplied each week, and unlike Zevaskyn it covers both recessive and dominant DEB. Most DEB care also involves specialized wound dressings, pain control, itch control, and nutrition support. Which combination is right for you is a conversation for your dermatologist or EB specialist, not something to decide from a price page.

Vyjuvek side effects and safety basics

Vyjuvek does not carry a boxed warning, and its FDA label lists no contraindications. In the clinical trials that supported approval (31 patients), the most common side effects, each reported in more than 5% of patients, were itching, chills, redness of the skin, rash, cough, and runny nose. The label notes that no drug interaction studies have been performed. Vyjuvek is for topical use on wounds only. It is not for injection, not for intravenous use, and is not to be used inside the body. It is not a controlled substance and is not habit-forming.

The one warning and precaution in the label concerns accidental exposure. Because Vyjuvek is made from a modified HSV-1 virus, the virus and viral DNA can be shed for a short time from treated wounds, dressings, and containers. Caregivers should wear protective gloves when preparing, applying, or handling treated wounds and dressings, and should follow the disposal instructions they are given. Avoid direct contact with treated wounds and with dressings from treated wounds until the next dressing change. If Vyjuvek accidentally splashes into the eyes or other mucous membranes, flush with clean water for at least 15 minutes. People who are pregnant should not prepare or apply Vyjuvek and should avoid direct contact with treated wounds or used dressings. As with any medicine, tell your care team about all the medicines and supplements you take and about your medical history before starting. This page is a price and information resource, not medical advice; talk with your healthcare provider or EB specialist about whether Vyjuvek is right for you and how to use it safely.